Status:
COMPLETED
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
Lead Sponsor:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Conditions:
Asthma; Eosinophilic
Eligibility:
All Genders
18-80 years
Brief Summary
In this study, investigators want to evaluation of the impact of benralizumab (Fasenra®, Astra Zeneca) on different cell populations, including basophils and innate lymphoid cells, and several biomark...
Detailed Description
For this: 1. Investigators will monitor basophil miRNAs changes with benralizumab analyzing miRNAS profile of isolated basophil before and after benralizumab treatment. 2. Also, in vitro characteriza...
Eligibility Criteria
Inclusion
- .It is mandatory that all patients can comprehend the study requirements and provide informed consent for their participation in MEGA.
- Group A:
- Adult people (≥ 18 and ≤ 80 years old) with eosinophilic severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without long-acting muscarinic antagonist or Montelukast or oral corticosteroids)
- Benralizumab treatment approved.
- Group B:
- .Patients with allergic asthma (prick test or RAST positive).
Exclusion
- Patients with continuous OCS treatment
- Patients with Immunosuppressive drugs
- Patients with primary or secondary immune deficiency,
- Patients with chronic or/and concomitant disease, presence of severe systemic disease or cancer,
- Patients with possible infestation by parasites.
- Patients with other acute or chronic active lung disorders Patients with significant psychiatric disorders
- Patients with biological treatment will be excludes for group B
Key Trial Info
Start Date :
September 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 13 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04742504
Start Date
September 7 2021
End Date
October 13 2023
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Investigación FJD
Madrid, Spain